---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-316995"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2026-07-27T13:08:03+00:00"
generated_at: "2026-07-27T13:09:06.915605+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sarepta names Michael Severino CEO effective July 28; Ingram retires

## Summary
- Michael Severino appointed CEO effective July 28, 2026; succeeds Doug Ingram who retires.
- Severino receives $1.18M base salary, 110% target bonus, and $35M sign-on equity grant.
- Ingram to serve as consultant through Dec 2026 at $15k/month consulting fee.
- Severino previously CEO of Tessera Therapeutics and Vice Chairman/President at AbbVie.
- Severino also appointed to Sarepta's Board of Directors as Class I director.

## SEC filing metadata
- accession: 0001193125-26-316995
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2026-07-27T13:08:03+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/0001193125-26-316995-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/d101719d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-316995
- JSON: https://secwatch.observer/filing/0001193125-26-316995.json
- Plain text: https://secwatch.observer/filing/0001193125-26-316995.txt

## Key facts
- Executive change
  Michael Severino was appointed as Class I director at Sarepta Therapeutics, Inc..
  - Action: appointed
  - Role: Class I director
  source text: Also on July 23, 2026, the Board appointed Dr. Severino, effective as of the Effective Date, as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/0001193125-26-316995-index.htm
- Executive change
  Michael Severino was appointed as Chief Executive Officer at Sarepta Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On July 23, 2026, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the “Company”) appointed Michael Severino, M.D. as Chief Executive Officer of the Company, effective July 28, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/0001193125-26-316995-index.htm
- Executive change
  Douglas Ingram departed as Chief Executive Officer at Sarepta Therapeutics, Inc..
  - Action: depart
  - Role: Chief Executive Officer
  source text: Mr. Ingram will depart from his position as Chief Executive Officer and a member of the Board as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/0001193125-26-316995-index.htm
- Executive change
  Douglas Ingram departed as member of the Board at Sarepta Therapeutics, Inc..
  - Action: depart
  - Role: member of the Board
  source text: Mr. Ingram will depart from his position as Chief Executive Officer and a member of the Board as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/0001193125-26-316995-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.